NNZ-2566

A board to discuss future MS therapies in early stage (Phase I or II) trials.

NNZ-2566

Postby bromley » Mon Mar 06, 2006 11:44 am

I have previously posted articles relating to Neuren Pharmaceuticals. Much of their research focuses on neuro-protection. Their website states that:

"The compounds developed by Neuren have application not only to acute brain injuries associated with stroke, cardiopulmonary bypass surgery (CPB) and traumatic brain injury but also in chronic neurological conditions such as Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis".

Their first key drug, Glypromate, is in Phase 2 trials (with the US Army). The company announced today that their second key drug is going into Phase 1 trials.


http://www.neurenpharma.com/


Ian
User avatar
bromley
Family Elder
 
Posts: 1887
Joined: Fri Sep 10, 2004 3:00 pm

Advertisement

Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post
  • NNZ-2566
    by bromley » Sat Mar 25, 2006 8:22 am
    0 Replies
    1307 Views
    Last post by bromley View the latest post
    Sat Mar 25, 2006 8:22 am

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service